Every 8-K that Amanat Acquisition Corp (AMAN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMAN filings page.
Amanat Acquisition Corp. entered into a business combination agreement with Corxel Pharmaceuticals, Inc. and its parent, Corxel Pharmaceuticals Limited, with an implied Corxel equity value of $200 million. PIPE investors agreed to purchase securities for aggregate commitments of $300 million, subject to contractual reduction mechanisms. The transaction is expected to close in the first half of 2027, subject to shareholder approvals, regulatory clearance and other closing conditions.
Assuming no AMAN shareholder redemptions and before transaction costs, the combined company is expected to receive approximately $377 million in gross proceeds. Net proceeds are expected to support the company through 2029 and fund global Phase 3 development of CX11. AMAN shareholders may redeem shares for their pro rata portion of the trust account. The transaction covers Corxel US and its obesity-focused assets; Corxel HK and JX10 remain outside it. Corxel reports that CX11 achieved mean body-weight reduction of up to 11.5% at Week 36 in a U.S. Phase 2 trial; treatment discontinuation due to gastrointestinal adverse events was 5.0%.
Amanat Acquisition Corp, a blank check company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000. Underwriters hold a 45‑day over‑allotment option for up to 1,125,000 additional shares at the same price.
Simultaneously, the sponsor bought 300,000 private placement shares for $3,000,000. As of May 20, 2026, $75,000,000, including $2,250,000 of deferred underwriting fees, was placed in a trust account for public shareholders. The audited balance sheet shows total assets of $77,227,475, with 7,500,000 Class A shares classified as redeemable at $10.00 per share and a shareholders’ deficit driven by offering-related costs and the redemption feature.
Amanat Acquisition Corp, a Cayman Islands-based special purpose acquisition company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000. The company also granted the underwriter a 45-day option to buy up to 1,125,000 additional shares at the same price to cover any over-allotments.
At the IPO closing, the sponsor purchased 300,000 private placement Class A shares at $10.00 each, providing an additional $3,000,000. A total of $75,000,000 of IPO and private placement proceeds was deposited into a U.S.-based trust account to fund a future business combination. The company has up to 24 months from the IPO closing to complete its initial business combination, with public shareholders given redemption rights if a deal is not completed or certain charter changes are proposed. Independent directors were appointed and the amended and restated charter became effective in connection with the IPO.